Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for amplifying PBMC by virtue of CD40 in combination with PD-L and cell factors

A cytokine, PD-L technology, applied in animal cells, vertebrate cells, cell culture active agents, etc., can solve the problem of high ratio of negative co-stimulatory molecules PD-1/PD-L1, achieve low equipment requirements, The effect of high collection rate, simple operation and time saving

Active Publication Date: 2019-01-22
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There are still many problems to be solved in the new adoptive immune cell therapy induced by CD3McAb combined with cytokines IL-2, IFN-γ, IL-1α: because IL-2 is used to maintain the proliferation of late T cells, and IL-2 The ratio of negative co-stimulatory molecule PD-1 / PD-L1 in induced lymphocytes is quite high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for amplifying PBMC by virtue of CD40 in combination with PD-L and cell factors
  • Method for amplifying PBMC by virtue of CD40 in combination with PD-L and cell factors
  • Method for amplifying PBMC by virtue of CD40 in combination with PD-L and cell factors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1: In vitro expansion and culture of adoptive immunotherapy cells

[0038] Isolation, extraction and expansion of PBMC

[0039] Peripheral blood from normal people was taken, diluted with PBS at a ratio of 1:2, and then subjected to Ficoll density gradient centrifugation. First add Ficoll, which has been placed at room temperature in advance, into the Fahrenheit tube, and then slowly add the diluted blood along the tube wall according to the ratio of Ficoll:diluted blood = 1:2 (the Ficoll tube is inclined at 45°, and the interface between Ficoll and the diluted blood should not be strongly shaking), and then centrifuged in a temperature-controlled centrifuge (1800rpm / min, 30min, 20-24°C). After centrifugation, 4 layers of liquid are obtained as shown in the figure below. The PBMC we need comes from the middle cloud layer. Carefully absorb the cloud layer cells with a pipette, then wash and centrifuge with 10 times the volume of PBS, and finally obtain PBMCs. ...

Embodiment 2

[0052] Example 2: Detection of immunophenotype of adoptive immunotherapy cells by flow cytometry

[0053] Flow cytometric detection of molecules on the membrane surface of cells

[0054] ① Transfer the cell suspension to a centrifuge tube, centrifuge at 1500rpm / min for 3min, and discard the supernatant.

[0055] ②Add PBS (containing 1% calf serum), centrifuge at 1500rpm / min for 3min, remove the supernatant, and repeat this step once more.

[0056] ③Set control group: negative control tube (only add unstained cells), single-label compensation tube.

[0057] ④Add PBS (containing 1% calf serum) to make a final concentration of 1×10 6 cells / ml of cell suspension.

[0058] ⑤Take 100μl of the cell suspension in step 4 and add it to a new tube.

[0059] ⑥ Add fluorescent antibody to the cell suspension and incubate for 30 min at room temperature in the dark.

[0060] ⑦Wash and centrifuge, add 500μl sheath fluid, and test on the machine.

[0061] On the 14th day of culture, the ...

Embodiment 3

[0075] Example 3: Detection of killing function in vitro

[0076] Flow cytometric detection of expression of IFN-γ in T lymphocytes

[0077] ① Add 100 μl of the prepared cell suspension to each flow loading tube, the number of cells is about 1x106.

[0078] ② Label surface antigens (CD3, CD4, CD8) according to the cell surface antigen staining method, and the dosage of fluorescent antibody is 2 μl / test.

[0079] ③ Wash the cells with pre-cooled PBS.

[0080] ④ Vortex to resuspend the cells, add 200 μl of Fixation / Permeabilization working solution (Fixation / Permeabilization), and mix again.

[0081] ⑤ Incubate at 4°C for 12 minutes in the dark.

[0082] ⑥ Add 500 μl Permeabilization Buffer working solution, centrifuge to wash the cells and discard the supernatant.

[0083] ⑦Repeat step 6 to wash the cells.

[0084] ⑧Add 100 μl of diluted fluorescent-labeled IFN-γ antibody (diluted with Permeabilization Buffer working solution) directly, and incubate at 4°C for 20 minutes i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for amplifying PBMC by virtue of CD40 in combination with PD-L and cell factors. The method comprises the following steps: (1) taking peripheral blood of normal people, mixing the peripheral blood of the normal people with PBS for dilution, and carrying out Ficoll density gradient centrifugation; (2) for 4 layers of liquid obtained after centrifugation, sucking middle cloud layer cells by adopting a pipette, and carrying out washing for centrifugation by adopting PBS with 10 times of volumes, thus obtaining PBMC; (3) preparing the PBMC cells into a cell suspension by adopting RMPI1640 complete medium, transferring the cell suspension into a 6-pore plate and a 24-pore plate, and adding corresponding cell factor solutions into each group of cell culture solution, placing the pore plates into a CO2 incubator, and carrying out culturing; and (4) supplementing the cell factor solutions once 2-3 days according to the state of the cells. According to the method, the preparation of novel adoptive immunotherapy cells through PBMC amplification by adopting CD40 signals in combination with PD-L1 and cell factors IL-15 and IL-7 is adopted as the entry point, and the novel in-vitro induction scheme of adoptive immunity cells is provided. In addition, the method provided by the invention has the advantages that the requirements on experimental facilities arelow, the operation is simple and time-saving, the collecting rate for the adoptive immunity cells is high, and the purity is high.

Description

technical field [0001] The present application relates to the field of biotechnology, in particular, to a method for expanding PBMCs by combining CD40 with PD-L and cytokines. Background technique [0002] Malignant tumor is one of the important diseases that seriously endanger human health. At present, surgery, radiotherapy, and chemotherapy are still the main treatment methods. However, the recurrence rate and mortality rate are still high. Adoptive cellular immunotherapy (ACT) is becoming a new treatment for malignant tumors after radiotherapy and chemotherapy. It mainly infuses sensitized lymphocytes (with specific immunity) to tumor patients to obtain anti-tumor immunity. . [0003] The effector cells of adoptive immunotherapy are heterogeneous, such as cytotoxic T cells (CTL), natural killer cells (NK), macrophages, lymphokine-activated killer cells (lymphokine-activated killer cells, LAK) and tumor infiltrating lymphocytes (tumor-infiltrating lymphocytes, TIL) and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/078
CPCC12N5/0634C12N2501/2301C12N2501/2302C12N2501/2307C12N2501/2315C12N2501/24C12N2501/51C12N2501/515C12N2501/52
Inventor 古彦铮张学光黄子逸刘翠平
Owner THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV